Back to search
FDAFDA · Food and drugs·Recall number D-0617-2020

Ranitidine Tablets, USP 150 mg, OTC, a.) 30 count bottle (NDC 68788-7078-03), b.) 60 count bottle (NDC 68788-7078-06), Mfg: Amneal Pharmaceuticals

Published December 18, 2019 · Recall initiated: December 2, 2019

Summary

FDA records drug Class II recall D-0617-2020, published December 18, 2019 and initiated December 2, 2019. Recalling firm: Preferred Pharmaceuticals, Inc; Status: Terminated; Reported quantity: 316 bottles; Lot: Lot #: I2519H, Exp. 12/20; I2719O, Exp. 12/20; J1419O, Exp. 12/20; J2819L, Exp. 12/20. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of NDMA impurity detected in product.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Preferred Pharmaceuticals, Inc
Distributor
CA, FL
Lot
Lot #: I2519H, Exp. 12/20; I2719O, Exp. 12/20; J1419O, Exp. 12/20; J2819L, Exp. 12/20
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ranitidine Tablets, USP 150 mg, OTC, a.) 30 count bottle (NDC 68788-7078-03), b.) 60 count bottle (NDC 68788-7078-06), Mfg: Amneal Pharmaceuticals recalled?

Yes. FDA published recall D-0617-2020 on December 18, 2019. Reported hazard: CGMP Deviations: Presence of NDMA impurity detected in product.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail